Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Search All MIN Lorem Company A LOC: Sector A Search All MIN Search by Name Search by Ticker ASX:RMD Healthcare Equipment and Supplies ResMed turns GLP-1 weight loss drugs from threat into market expansion story Fears that GLP-1 obesity drugs would shrink the pool of sleep apnoea patients needing CPAP therapy have given way to a fund manager consensus that the drugs are instead growing ResMed's addressable market by driving more people into the sleep channel
121 Overall, these data accumulate to show that GLP-1 RAs provide not only metabolic and mitochondrial effects but also meaningful clinical impact for vascular and neuroendocrine protection that may ultimately decrease age-related decline in cardiovascular health, musculoskeletal health, and cognitive health
Learn more: Lilly Medical US Impressive findings
[23] [13] Nausea is most common during the first week of GLP-1 therapy and typically improves significantly within 24 weeks as your body adjusts to the medication
HchenbergerROhlaK
FIGURE 3 To functionally link the altered SCFAs to GLP-1 secretion, we employed GLUTag cells under high-glucose (HG) conditions to mimic diabetic enteroendocrine dysfunction
